Active	Status	Sponsor type	Region	Phase	Filter
5 Active 2 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hare, Josh
DCMII, NCT04476901: Administration of Allogeneic-MSC in Patients with Non-Ischemic Dilated Cardiomyopathy	Recruiting	2	136	US	allogeneic human mesenchymal stem cells (hMSCs), Placebo	Joshua M Hare, United States Department of Defense, The University of Texas Health Science Center, Houston	Non-ischemic Dilated Cardiomyopathy	12/25	12/25
Delgado, Cindy
SARO.20.002, NCT05011305: Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis	Active, not recruiting	2	180	US, RoW	Saroglitazar Magnesium 2 mg, Investigational Product, Saroglitazar Magnesium 4 mg, Placebo, Comparator Agent	Zydus Therapeutics Inc.	Nonalcoholic Steatohepatitis, Fibrosis	07/25	07/25
TEST, NCT05260268: Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant	Recruiting	N/A	360	US	TEST Intervention	University of Pennsylvania, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Liver Transplant; Complications, Cirrhosis, End Stage Liver DIsease, Medication Adherence	07/26	01/27
Caceres, Lina
DCMII, NCT04476901: Administration of Allogeneic-MSC in Patients with Non-Ischemic Dilated Cardiomyopathy	Recruiting	2	136	US	allogeneic human mesenchymal stem cells (hMSCs), Placebo	Joshua M Hare, United States Department of Defense, The University of Texas Health Science Center, Houston	Non-ischemic Dilated Cardiomyopathy	12/25	12/25
GenePHIT, NCT05598333: Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects with Non-Ischemic NYHA Class III Heart Failure	Recruiting	2	150	US	AB-1002, Gene Therapy, NAN-101	Asklepios Biopharmaceutical, Inc.	Congestive Heart Failure	10/26	12/30